TPE Knowledge Center reSound™ Ultra-Low Carbon Footprint TPEs Healthcare TPEs: Versaflex™ HC

Please note all previously entered data will be modified. Please note all previously entered data will be modified. Substances 103­23­1, Bis(2­ethylhexyl) adipate 103­23­1, Bis(2­ethylhexyl) adipate Substances Section Data Statement of Intent Are the following included in the Facility's TRA Plan?

Technical Data Sheets Safety Data Sheets Safety Data Sheets

To find out more about TPE materials specifically formulated for skin sensitivity and wearable electronic applications, click here: Versaflex™ CE Series

To find out more about TPE materials specifically formulated for headphones, stereo speakers, smartwatches, gaming consoles and more, click here: Versaflex™ CE Series

Technical Data Sheets Safety Data Sheets Safety Data Sheets

ELAUSA ELECTRONICS V E H I C L E L I G H T H E A T S I N K • Replace aluminium to reduce part cost and weight • Maintain similar thermal transition to current material • Simplify manufacturing • Reduced part weight from 38g to 9g • Provided the required thermal efficiency through part re-design and material choice • Enabled upfront simulation data through Avient Design reducing risk of metal replacement • Simplified manufacture process to a single injection molding step Therma-Tech™ Thermally Conductive Formulations KEY REQUIREMENTS WHY AVIENT?

KUNSTSTOFF SCHWANDEN E L E C T R I C V E H I C L E P A R T • Replace aluminum to reduce part weight and overall weight of the electric vehicle • Secure supply of high volume of material • Flexible delivery • Cost competitive • Enabled OEM to replace metal and reduce part weight • Provided excellent customer service, sending samples and technical data promptly • Supported customer with processing queries • Secured material supply and flexible delivery – delivering on a specific date each month Maxxam™ Polyolefin Formulations KEY REQUIREMENTS WHY AVIENT?

TPE Knowledge Center GLS™ TPEs with Antimicrobial Technologies reSound™ Ultra-Low Carbon Footprint TPEs

We are Avient. 6 B ET T E R TO G E TH E R : P O LYO NE A N D C L A R I A N T C O LO R Key Financial Data (1) 2021E Sales $4.75 billion 2021E EBITDA $580 million 87% of EBITDA from specialty applications (1) As of October 28, 2021 webcast Synergies ($ millions) Three-Year Estimate Administrative $ 20 Sourcing 30 Operational 25 Total Synergies $ 75 7 C L A R I A N T C O S T S Y N ERG I E S • On-track to realize $50 million of expected synergies in 2021 – up from earlier estimate of $35 million • Relentless focus on guiding principles for acquisition integration: safety first, employee collaboration and exceeding customer expectations • Future revenue synergies in excess of $50 million by 2025 are not part of these estimates and represent additional growth over the long term 8 • Barrier technology • Functional additives • Processing aids • Flame retardants • Light-weighting additives Complementary Technologies • Clariant’s approved formulations and certified facilities • Legacy PolyOne’s leading share in distribution channels Healthcare Solutions • Clariant’s position in SE Asia, Latin America, Germany & Italy • Legacy PolyOne’s position in U.S., Canada and China Regional Strengths • Solutions with Avient’s engineered materials customers • Avient’s distribution channels Segment Cross-selling C O M P L E M E NTA RY T E C H N O LOG I E S A N D C U S TO M ER S D R I V E R E V E N U E S Y N E RG I E S Revenue synergy opportunities in excess of $50M by 2025 The complementary aspects of our combined businesses are unquestionable. D is t. ) K W R P P G A V Y F U L R P M G C P F M C H X L H U N E C L A S H E M N C E S C L Source: Peer data per Bloomberg market data as of November 8, 2021 Avient reflects 2021 estimated revenue of $4,750M and estimated CAPEX of $80M (excludes one-time synergy capture CAPEX of $20M) Avient Specialty Formulators Other Chemical/Specialty Companies Free Cash Flow Conversion (1) 2021E (%) Being asset light helps us to generate strong free cash flow that is in line with specialty formulators. Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA H I G H F R E E C A S H F L OW C O N V E R S I O N Avient reflects 2021 estimated EBITDA of $580M and estimated CAPEX of $80M (excludes one-time synergy capture CAPEX of $20M) Source: Peer data per Bloomberg market data as of November 8, 2021 86 93 85 83 79 77 75 89 85 83 81 79 79 78 77 74 25 A vi e n t K W R P P G A V Y F U L R P M G C P F M C U N V R C E B N R H X L A S H E C L E M N H U N S C L A L B (10) Source: Peer data per Bloomberg market data as of November 8, 2021 Total Enterprise Value / 2021E EBITDA Our current valuation with updated guidance implies an EBITDA multiple that is below many of our specialty formulator peers.